Combination Therapies

Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases

  • Allan L. Goldstein
  • Enrico Garaci

Table of contents

  1. Front Matter
    Pages i-xv
  2. Combination Immunotherapy: Molecular, Cellular, and Gene Approaches

    1. Front Matter
      Pages 1-1
    2. Robert Peter Gale, Anna Butturini
      Pages 13-17
    3. A. Fefer, C. Higuchi, M. Benyunes, C. Beach, C. Lindgren, C. D. Buckner et al.
      Pages 19-28
    4. Gilda G. Hillman, Sudha Sud, Eric J. Dybal, J. Edson Pontes, Gabriel P. Haas
      Pages 39-48
  3. Clinical Applications of Combination Chemoimmunotherapy in Cancer

    1. Front Matter
      Pages 49-49
    2. G. T. Budd, S. V. Murthy, J. Finke, R. R. Tubbs, J. Alexander, S. Gautam et al.
      Pages 49-55
    3. Robert A. Figlin, Antoine S. Abi-Aad, Arie Belldegrun, Jean B. deKernion
      Pages 57-65
    4. Franco Dammacco, Giuseppe Avvisati, Mario Boccadoro, Vito Michele Lauta, Rita Di Stefano, Alessandro Pileri et al.
      Pages 67-72
    5. G. S. Del Giacco, G. Mantovani, V. Arangino, F. Locci, A. C. Scanu, G. Pusceddu
      Pages 79-85
    6. Cristina Jemma, Stefania Vai, Tiziana Musso, Massimo Geuna, Guido Valente, Guido Forni
      Pages 87-96
  4. Combination Approaches and Gene Therapy in the Treatment of AIDS and Other Infectious Diseases

    1. Front Matter
      Pages 97-97
    2. Luigina Romani, Simonetta Mocci, Franca Campanile, Paolo Puccetti, Francesco Bistoni
      Pages 97-104
    3. Evan M. Hersh, Carole Y. Funk, Eskild A. Petersen
      Pages 113-122
    4. Prem S. Sarin, Allan Goldstein, S. Agrawal, Paul Zamecnik
      Pages 123-129
    5. Judith Hsia, Ting Tang
      Pages 131-137
    6. William B. Ershler, Stefan Gravenstein
      Pages 139-147
    7. Milton G. Mutchnick, Glen D. Cummings, Jay H. Hoofnagle, David A. Shafritz
      Pages 149-157
    8. Antonio Cassone, Antonella Torosantucci, Carla Palma, Maria J. Gomez, Clara M. Ausiello, Julie Y. Djeu
      Pages 159-166
    9. C. F. Perno, A. Bergamini, G. Milanese, M. Capozzi, G. Zon, R. Calio et al.
      Pages 167-176
  5. Mechanism of Action and Synergy between Drugs, Biological Response Modifiers, and/or Vaccines in Combination Therapies

    1. Front Matter
      Pages 177-177
    2. J. W. Hadden, P. H. Malec, M. Sosa, E. M. Hadden
      Pages 177-184
    3. Jules E. Harris, Donald P. Braun
      Pages 197-206
    4. Alan D. Schreiber, Arnold I. Levinson, Milton D. Rossman
      Pages 207-214
    5. C. De Simone, E. Arrigoni Martelli, G. Famularo, P. Foresta, V. Ruggiero, R. Giacomelli et al.
      Pages 223-229
    6. J. E. Kirkley, Paul H. Naylor, Dante J. Marciani, Charlotte R. Kensil, Mark Newman, A. L. Goldstein
      Pages 231-236
    7. Charles H. Evans, Paulette M. Furbert-Harris, Anath A. Flugelman, Craig D. Woodworth, Joseph A. DiPaolo
      Pages 237-244
  6. Prospects and Future Directions Using Animal Models to Define Effective Combination Therapies with Biological Response Modifiers

    1. Front Matter
      Pages 269-269
    2. Robert H. Wiltrout, Giovanna Damia, Martin MacPhee, Hitoyasu Futami, Connie R. Faltynek, Dan L. Longo et al.
      Pages 269-274
    3. Cartesio Favalli, Antonio Mastino, Sandro Grelli, Francesca Pica, Guido Rasi, Enrico Garaci
      Pages 275-281
    4. F. Belardelli, L. Gabriele, E. Proietti, U. Testa, C. Peschle, I. Gresser
      Pages 283-291
    5. L. D’Tentori, S. Atri, A. Giuliani, P. Puccetti, M. C. Fioretti, V. Nistico’ et al.
      Pages 293-301
  7. Back Matter
    Pages 303-313

About this book


Over the past decade many of the key lymphokines, hormones and growth factors that help regulate the immune system have been defined. These molecules, termed biological response modifiers (BRMs) , have been sequenced, synthesized and produced in large enough quantities to test in animals and humans resulting in the development of new approaches to the treatment of human disease, in particular, cancers and infectious diseases. Advances in this area have also led to rethinking therapies against a range of autoimmune disorders and other diseases associated with immune and endocrine imbalances. BRMs currently are being applied clinically as both primary and adjunctive therapy to enhance the effectiveness of traditional treatments by maximizing their activities and to protect critical tissues against intolerable chemotherapeutic and radiation damage. Present constraints against the use of BRMs revolve around the nature of these substances in vivo, where many of their actions and the majority of their interactions and synergies remain to be elucidated. For example, as these molecules are thought to exert their effects locally, the systemic administration of lymphokines, cytokines and growth factors at doses adequate to produce a wanted anti-tumor effect in many instances is intolerably toxic. Efforts to overcome this formidable problem have led scientists to begin to explore the transfer of genes known to encode for these molecules into cells which otherwise inadequately elicit or produce anti-tumor or anti-infective responses.


AIDS gene therapy infections infectious disease therapy

Editors and affiliations

  • Allan L. Goldstein
    • 1
  • Enrico Garaci
    • 2
  1. 1.The George Washington University School of MedicineUSA
  2. 2.University of Rome “Tor Vergata”RomeItaly

Bibliographic information

  • DOI
  • Copyright Information Plenum Publishing Corporation 1992
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4613-6472-6
  • Online ISBN 978-1-4615-3340-5
  • Buy this book on publisher's site